U.S. Markets open in 4 hrs 19 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
153.02-3.49 (-2.23%)
At close: 4:00PM EDT
People also watch
  • Per Caroline Chen over at Bloomberg News -- "$amgn sees cardiovascular safety signal in romo arch trial- now doesn't expect approval in 2017 (prev pdufa July)"
  • Looking forward to the FDA approval on Erenumab. I needed it, this roller-coasting AMGN stock is giving me migraine headache.
  • This stock is so oversold buy buy buy buy
  • Joint Amgen/Novartis migraine drug will be a blockbuster! Forget about osteo drug, it will come on later. Look at NVS stock price--news about this drug is not discussed much by Amgen press but it has moved NVS stock up nicely! Amgen to follow once market makers have bought enough shares at low prices.
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets



    Clyra Medical | Make Life Better
  • what happned to this toad?
  •  Andrew Edmonds  May 12, 2017

    Dividend hunters beware, Amgen (NASDAQ:AMGN) will pay its upcoming dividend of $1.15 on the Thu 08 Jun 2017 and will start trading ex-dividend on the Mon 15 May 2017. Should dividend investors care? Today I’m going to investigate the latest data and analyze some metrics you shouldn’t overlook.

    What is the ex-dividend date?
    If you purchase a stock on or after its ex-dividend date, you will not receive the next dividend payment. Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
  • Pos litigious
  • CHRS soured 8.5 north due to Humira (ABBV) patent court case; AMGN will follow (8.5% or more north). It is a matter of days or weeks.
  • #$%$???? The dow is up 165 and again all my biotechs are down today! What's going on at that shareholder meeting today?
  • 3 fer 1 split makes good sense; this puppy weyy over-sold, no brainer
  • Amgen, Inc. (AMGN) to Issue Quarterly Dividend of $1.15 on June 8th

    https://www.baseball-news-blog.com › Investing

    13 hours ago - Amgen, Inc. (NASDAQ:AMGN) announced a quarterly dividend on Tuesday, March 7th. Shareholders of record on Wednesday, May 17th will be paid a dividend ...

  • Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
    San Francisco Bay Area 500+ 500+ connections
    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
  • The Bank of New York Mellon has over 1/3 Billion dollars in faith in AMGN & investors should too :

    Amgen Inc. (AMGN) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on May 11, 2017.

    On May 11, 2017, Amgen Inc. (the "Company") issued and sold $300,000,000 of its Senior Floating Rate Notes due 2019 (the "2019 Floating Rate Notes"), $300,000,000 of its Senior Floating Rate Notes due 2020 (the "2020 Floating Rate Notes" and, together with the 2019 Floating Rate Notes, the "Floating Rate Notes"), $700,000,000 of its 1.900% Senior Notes due 2019 (the "2019 Fixed Rate Notes"), $700,000,000 of its 2.200% Senior Notes due 2020 (the "2020 Fixed Rate Notes") and $1,500,000,000 of its 2.650% Senior Notes due 2022 (the "2022 Fixed Rate Notes" and, together with the 2019 Floating Rate Notes, the 2020 Floating Rate Notes, the 2019 Fixed Rate Notes and the 2020 Fixed Rate Notes, the "Notes"). The Notes are registered under an effective Registration Statement on Form S-3 (Registration No. 333-216060) (the "Registration Statement"), filed on February 14, 2017, and were issued pursuant to an indenture, dated as of May 22, 2014 (the "Indenture"), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, and an officer's certificate, dated as of May 11, 2017 (the "Officer's Certificate"), setting forth the terms of the Notes. Net proceeds to the Company from the offering were approximately $3,483,548,000, after deducting underwriters' discounts and estimated offering expenses payable by the Company.
  • I believe AMGN has refinanced at a lower rate of interest in order to make a large acquisition.
    JMO, Dr. J
    Amgen, Inc. (AMGN) Raised to “Strong-Buy” at Vetr Inc. - Markets Daily


    14 hours ago - Amgen, Inc. (NASDAQ:AMGN) was upgraded by equities research analysts at Vetr from a ... has a $179.72 target price on the medical research company's stock.

  • REITs
    Dividend Ideas
    Dividend Strategy
    Dividend News
    Dividend Quick Picks
    Editor's Picks
    S&P 500 2,380.64 0.00 (0.00%)
    Dow 20,876.20 0.00 (0.00%)

    All PortfoliosportfolioPortfolio 1Portfolio 2+ Create New Portfolio


























    Similar Investors Follow:









    Better Healthcare Dividend Stock: Johnson & Johnson Or Amgen?

    May 10, 2017 2:31 PM ET
    About: Johnson & Johnson (JNJ), Includes: AMGN

    Sure Dividend

    Sure Dividend

    Long-term horizon, newsletter provider, dividend investing, High Quality Dividends

    Sure Dividend (High Quality Dividend Growth Stocks)




    Johnson & Johnson has increased its dividend for 55 years in a row. Its dividend track record is unbeatable in the health care sector.

    It is hard to even fathom that there could be a better dividend growth stock than J&J.

    J&J is the most stable health care stock, but Amgen could be a more attractive stock for dividend growth.

    Written for Sure Dividend by Bob Ciura

    The health care sector is loaded with high-quality dividend stocks. This includes relative newcomers to dividends such as Amgen (NASDAQ:AMGN), which has only paid a dividend since 2011, as well as dividend stalwarts such as Johnson & Johnson (NYSE:JNJ), which has increased its dividend for 55 years in a row. Not only is J&J a Dividend Aristocrat, but it is also one of 19 Dividend Kings, an exclusive group stocks with 50+ consecutive years of dividend increases.

    At first glance, J&J seems to blow all other health care stocks out of the water, thanks to its long history of annual dividend growth. But just because Amgen hasn't paid a dividend as long as J&J does not automatically disqualify it from consideration. It is actually a highly attractive stock for dividend growth.

    This article will compare and contrast these two giant health care dividend stocks.
  • AXSM (MC $85 M)(Cash $60 M) 5x BIG Phase 3 in various indications targeting large Markets with first results in Q3 2017 = 2000% POTENTIAL..UNKNOWN low float Stock !!! A BIG LIFETIME OPPORTUNITY GUYS ! GLTA

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $60 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $60.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Amgen Inc. (AMGN) Isn’t Shy About Revealing Its Soul In The Technicals

    Jfry Banks
    May 10, 2017
  • https://finance.yahoo.com/news/navidea-posts-1q-profit-235432297.html

    Navidea posts 1Q profit
    The Dublin, Ohio-based company said it had profit of 52 cents per share. Losses, adjusted to account for discontinued operations, came to 1 cent per share. The biopharmaceutical posted revenue of $580,000 ...